RNF181 promotes malignancy of glioma cells along Hippo / Yap signaling pathway
PEI Meijuan1, SUN Zhonglei2, HUANG Shengxuan3, LIU Yingfu4, LI Xuewen5
1. Department of Neurology, 5. Department of General Practice, Characteristic Medical Center of PAP, Tianjin 300162, China; 2. Department of Neurosurgery, Central Hospital of Zaozhuang Mining Group, Zaozhuang 277100, China; 3. Department of Neurosurgery, Sanming First Hospital Affiliated to Fujian Medical University, Sanming 365000, China; 4. Cangzhou Nanobody Technology Innovation Center, Cangzhou 061000, China
Abstract：Objective To explore the effect of overexpression of RNF181 on the malignancy of human glioma SHG44 cells and the possible mechanism. Methods Human glioma cell line SHG44 was cultured in vitro. The adenovirus expression vector was transfected to overexpress RNF181. The effects of overexpression of RNF181 on the growth and proliferation of tumor cells, cell stemness, invasion and metastasis in vitro were compared. The expressions of RNF181 and hippo / Yap were detected by Western blot, and the relationship between RNF181 and hippo / Yap was clarified. Finally, the expressions of RNF181 and Yap in SHG44 cells were analyzed by immunofluorescence co-localization. Results After transfection, the relative expression levels of RNF181 mRNA and protein in SHG44 were [(1.95±0.06) and (0.39±0.06)], which were much higher than those of the control group [(1.05±0.03) and (0.23±0.06) ] and the negative group[ (1.03±0.04) and (0.24±0.07)], and the difference was statistically significant (P<0.05). The relative expression levels of YAP mRNA and protein were (1.02±0.04), and (0.29±0.05) in the control group, compared with[(1.03±0.05) and (0.31±0.07)] in the negative group, and [(2.63±0.12) and (0.71±0.06)]in the overexpression group, so the difference was statistically significant (P<0.05). MTT, immunofluorescence and Transwell assay confirmed that the proliferation rate of the RNF181 overexpression group was significantly higher than that of the control group and the negative group. The cell number of the RNF181 overexpression group was significantly larger than that of control group and negative group, so was the number of SHG-44 transmembrane cells. Immunofluorescence co-localization showed that RNF181 and YAP were co-expressed in the nucleus of SHG44. Conclusions Overexpression of RNF181 may contribute to the proliferation and invasion of glioma cells along the Hippo/Yap signaling pathway.
Ouyang T, Meng W, Li M, et al. Recent advances of the hippo/YAP signaling pathway in brain development and glioma[J]. Cell Mol Neurobiol, 2020,40(4):495-510.
[4]
Wang L, Zhang Z, Yu X, et al. Unbalanced YAP-SOX9 circuit drives stemness and malignant progression in esophageal squamous cell carcinoma[J]. Oncogene,2019,38(12):2042-2055.
[5]
Zhou R, Ding Y, Xue M, et al. RNF181 modulates hippo signaling and triple negative breast cancer progression[J]. Cancer Cell Int,2020,20:291.
[6]
Pedersen S M, Chan W, Jattani R P, et al. Negative regulation of CARD11 signaling and lymphoma cell survival by the E3 ubiquitin ligase RNF181[J]. Mol Cell Biol, 2015,36(5):794-808.
[7]
Knudsen K M, Moen G, Fluge O, et al. Pseudoprogression in high-grade glioma[J]. Acta Neurol Scand Suppl, 2013(196):31-37.
[8]
Wang Y, Pan P, Wang Z, et al. β-catenin-mediated YAP signaling promotes human glioma growth[J]. J Exp Clin Cancer Res, 2017,36(1):136.
[9]
Ouyang T, Meng W, Li M, et al. Recent advances of the hippo/YAP signaling pathway in brain development and glioma[J]. Cell Mol Neurobiol,2020,40(4):495-510.
[10]
Kim M H, Kim J. Role of YAP/TAZ transcriptional regulators in resistance to anti-cancer therapies[J]. Cell Mol Life Sci,2017,74(8):1457-1474.
[11]
Thompson B J.YAP/TAZ:drivers of tumor growth,metastasis,and resistance to therapy[J].Bioessays,2020,42(5):e1900162.
[12]
Nguyen C D, Yi C. YAP/TAZ signaling and resistance to cancer therapy[J]. Trends Cancer, 2019,5(5):283-296.
[13]
Yang Y K, Yang C, Chan W, et al. Molecular determinants of scaffold-induced linear ubiquitinylation of B cell lymphoma/leukemia 10 (Bcl10) during T cell receptor and oncogenic caspase recruitment domain-containing protein 11 (CARD11) signaling[J]. J Biol Chem,2016,291(50):25921-25936.
[14]
Gupta A, Jain R, Wahi D, et al. Abrogation of auroraA-TPX2 by novel natural inhibitors: molecular dynamics-based mechanistic analysis[J]. J Recept Signal Transduct Res, 2015,35(6):626-33.
2021, Vol. 32 
